GAMMA Investing’s Capricor Therapeutics CAPR Stock Holding History

GAMMA Investing’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.04K	Sell	321 -2	-0.6%	-$22	﹤0.01%	3835
2026 Q2	$7.78K	Buy	323 +36	+13%	+$1.09K	﹤0.01%	3306
2026 Q1	$8.72K	Buy	287 +234	+442%	+$6.24K	﹤0.01%	3141
2025 Q4	$1.53K	Sell	53 -42	-44%	-$548	﹤0.01%	3677
2025 Q3	$685	Buy	+95	New	+$699	﹤0.01%	3673
2025 Q1	–	Sell	-10	Closed	-$138	–	3810
2024 Q4	$138	Buy	+10	New	+$175	﹤0.01%	3747

Other funds holding CAPR

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

GAMMA Investing's CAPR Position: Q3 2026 in Review

GAMMA Investing reduced its Capricor Therapeutics (CAPR) stake by 0.62% in Q3 2026, selling an estimated $22 and leaving 321 shares worth $3.04K. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

GAMMA Investing first reported a position in CAPR in Q4 2024 and has held it in 6 quarters since. The position peaked at $8.72K in Q1 2026. 4 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

GAMMA Investing held 321 shares of Capricor Therapeutics worth $3.04K as of Q3 2026.
GAMMA Investing sold 2 Capricor Therapeutics shares in Q3 2026, an estimated $22.
Capricor Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3835 holding.
GAMMA Investing first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 6 quarters since.
GAMMA Investing's Capricor Therapeutics position peaked at $8.72K in Q1 2026.
4 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.